Mesoblast Limited · ASX:MSB
Mesoblast — Global Stem Cell Conference (October 2005)
21 slides from Mesoblast's conference presentation, Oct 19, 2005
Slide 1: Today's Clinical Reality
the adult stern cell company Today’s Clinical Reality Silviu Itescu, MD Founder and Chief Scientific Adviser October 2005
Slide 2: Snapshot
mesoblast the adult stern cell company snapshot listed Australian stock exchange Dec. 04 current market cap circa US $60m approx 800 shareholders tight register with building liquidity strong board and management cash at 30 June 2005 $15m (Angio $2.6m) sufficient cash through to filing of INDs
Slide 3: Our vision - a world leader in the treatment of orthopedic disease
Slide 4: Mesoblast
4 mesoblast
Slide 5: Competitive landscape - adult stem cells
Slide 6: Technology Advantages Enable Efficient MPC Isolation, Expansion and Differentiation
Technology Advantages Enable Efficient MPC Isolation, Expansion and Differentiation
Slide 7: Mesoblast
45 mesoblest
Slide 8: Mesoblast
4 pmesoblast
Slide 9: Mesoblast
4 pmesoblast
Slide 10: Femur resection model
» 25-30% of the mid portion of the femur is resected. « Structural stability maintained by intramedullary nail locked proximally and distally by transfixing screws.
Slide 11: Control animal vs MPC transplant months post-transplant
CONTROL ANIMAL TEST ANIMAL TEST ANIMAL 6 months post- 6 months post- 12 months post- sham transplant MPC transplant MPC transplant
Slide 12: Mesoblast
a “pmesodiest
Slide 13: Mesoblast
pmesodiast
Slide 14: Mesoblast
a. pmesodlast
Slide 15: CD12+ MPC In Bone Marrow And In Other Tissues Are Vascular Pericytes
CA12+ MPC In Bone Marrow And In Other Tissues Are Vascular Pericytes Human Bone Marrow MPC
Slide 16: MPC Therapy Results In Improved Heart Function
Slide 17: Mesoblast
ay mesoblast
Slide 18: Mesoblast
a pmesoblast
Slide 19: Mesoblast
ae mesoblest
Slide 20: Creating Value For Shareholders
Creating Value For Shareholders cancii
Slide 21: Mesoblast
4 pmesodlast
Mesoblast — Global Stem Cell Conference (October 2005) on 6ix